RDX-013 is under clinical development by Ardelyx and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect RDX-013’s likelihood of approval (LoA) and phase transition for Hyperkalemia took place on 05 May 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RDX-013 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
RDX-013 is under development for the treatment of hyperkalemia in patients with chronic kidney disease (CKD/ESRD) and heart failure. It is administered through oral route. The drug candidate is developed based on Ardelyx primary enterocyte and colonocyte culture system (APECCS) technology platform. It acts on non-systemic colonic potassium channel openers.
Ardelyx, is a pharmaceutical company. It is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company offers products that include tenapanor, and RDX013. Its products are used for hyperphosphatemia in patients with end-stage renal disease; constipation-predominant irritable bowel syndrome; and hyperkalemia, in chronic kidney disease patients. Ardelyx develops proprietary drug discovery and design platform to discover and design novel drug candidates such as tenapanor and others. The company works in partnership with pharmaceutical and biotechnology companies to discover small molecule drugs. Ardelyx is headquartered in Fremont, California, the US.
Quick View RDX-013 LOA Data
|Highest Development Stage|